Laboratory and clinical studies on teicoplanin

Yoshitsugu Miyazaki, Yasuhito Higashiyama, Haruko Matsuda, Kohtaro Mitsutake, Yuko Yamashita, Kenichi Tanaka, Masanori Iwamoto, Shigefumi Maesaki, Atsuro Hashimoto, Kazunori Tomono, Hironobu Koga, Shigeru Kohno, Kohei Hara, Chikako Mochida, Kazuyuki Sugawara, Mitsuo Kaku, Takakazu Ohtsubo, Hiroshi Yamada, Yuichi Inoue, Kohichi Watanabe

Research output: Contribution to journalArticlepeer-review


A newly developed glycopeptide antibiotic, teicoplanin (TEIC), was evaluated in vitro and in vivo in comparison with imipenem, ceftazidime, ceftizoxime, cefuzonam, piperacillin, KT-3777, cefaclor, cefixime, amoxicillin, vancomycin, cefotiam and minocycline. The results were as follows, 1) Antimicrobial activity : Minimum inhibitory concentrations (MICs) against 180 clinical isolates including 5 different species were determined by the microbroth dilution method. TEIC showed excellent antimicrobial activity against gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). 2) Clinical efficacy and adverse reactions : 8 patients with infections such as sepsis, pneumonia and pulmonary abscess were treated with TEIC, and the overall efficacy was good in 3 cases, poor in 1 case and unjudged in 4 cases. Fever was observed in 1 case as a side effect of TEIC. Eosinophilia in 1 case and elevation of GOT and GPT in 1 case were also observed as abnormal laboratory findings, however, they were mild and transient, and improved rapidly after the completion of TEIC treatment.

Original languageEnglish
Pages (from-to)190-195
Number of pages6
Publication statusPublished - 1993


  • MRSA
  • Teicoplanin
  • glycopeptide

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on teicoplanin'. Together they form a unique fingerprint.

Cite this